<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03121287</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 2015.006</org_study_id>
    <secondary_id>HUM00097162</secondary_id>
    <nct_id>NCT03121287</nct_id>
  </id_info>
  <brief_title>Early Imaging Biomarkers in NSCLC</brief_title>
  <official_title>Early Imaging Biomarkers to Predict Radiation-Induced Cardiopulmonary Toxicity in Patients With Thoracic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Rogel Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan Rogel Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if cardiac MRI, blood biomarkers, and lung CT
      scans can detect early changes to the associated with radiation therapy in patients receiving
      radiation treatment for thoracic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study seeks to investigate the utility of novel imaging biomarkers, namely whole lung
      volumetric CT scans and cardiac MRI, to non-invasively identify early pathologic changes in
      pulmonary and cardiac function resulting from thoracic radiation. The ability to identify
      these changes during the course of treatment offers a powerful tool to optimize radiation
      dose distributions within uninvolved normal tissue by adapting treatment to the individual
      patient response. In addition it may lead to other therapeutic interventions designed to
      reduce long term cardiopulmonary toxicity.

      The cardiac MRI will be performed using Aminophylline, Gadopentetate Dimeglumine and
      Regadenoson. These are not FDA approved for this purpose, but are being used off label and
      are IND exempt. Additionally, patients will be consented with an optional choice to retain
      research blood samples for 15 years after the completion of the study. This will allow
      cutting edge analysis for biomarkers that may be discovered in the future.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 23, 2015</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Lung Function</measure>
    <time_frame>1 Year post treatment</time_frame>
    <description>To characterize longitudinal changes in lung function using a voxel-wise image analysis technique of whole-lung CT scans in patients undergoing intrathoracic radiation therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Myocardial Tissue</measure>
    <time_frame>1 Year post treatment</time_frame>
    <description>To assess longitudinal changes in myocardial tissue and coronary vasculature physiology, using cardiac MR in patients undergoing intrathoracic radiation therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Myocardial Tissue</measure>
    <time_frame>1 Year post treatment</time_frame>
    <description>To assess longitudinal changes in myocardial tissue and coronary vasculature physiology, including microvascular dysfunction, using cardiac MR in patients undergoing intrathoracic radiation therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Myocardial Tissue</measure>
    <time_frame>1 Year post treatment</time_frame>
    <description>To assess longitudinal changes in myocardial tissue and coronary vasculature physiology, including diffuse fibrosis, using cardiac MR in patients undergoing intrathoracic radiation therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation Predictors from Baseline in Cardiopulmonary Changes</measure>
    <time_frame>1 Year post treatment</time_frame>
    <description>To explore radiation dosimetric predictors of CT- and MR-detectible cardiopulmonary changes.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Radiation Induced Change from Baseline in Imaging</measure>
    <time_frame>6 month and 1 year post treatment</time_frame>
    <description>To determine if early imaging-based changes are associated with radiation induced pulmonary and cardiac injury at 6- and 12-months</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">23</enrollment>
  <condition>Thoracic Cancer</condition>
  <arm_group>
    <arm_group_label>Lung or Esophageal Patients</arm_group_label>
    <description>Patients with lung or esophageal cancer undergoing conventionally-fractionated radiation therapy. Interventions to be administered include: Imaging Biomarkers using Volumetric CT Scans, Pulmonary using Pulmonary Function Test &amp; 6Minute Hall Walk, Imaging using Cardiac MRI, Specimen Collection using Blood Draws.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Imaging Biomarkers</intervention_name>
    <description>Whole lung volumetric CT scans</description>
    <arm_group_label>Lung or Esophageal Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pulmonary</intervention_name>
    <description>Pulmonary Function Tests &amp; 6 minute hall walk</description>
    <arm_group_label>Lung or Esophageal Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Imaging</intervention_name>
    <description>Cardiac MRI</description>
    <arm_group_label>Lung or Esophageal Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Specimen Collection</intervention_name>
    <description>Blood draw</description>
    <arm_group_label>Lung or Esophageal Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing conventionally-fractionated intrathoracic radiation therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients receiving once daily fractionated intrathoracic radiation therapy for:

          -  Stage IIA-IIIB non-small cell lung cancer

          -  Limited stage small cell lung cancer

          -  Stage I-III esophageal cancer (neoadjuvant or definitive)

          -  Patients must be 18 years of age or older

          -  Must not be claustrophobic

          -  Must have adequate kidney function

        Exclusion Criteria:

          -  Patients with small cell lung cancer receiving twice daily (b.i.d.) radiation

          -  Patients with esophageal cancer receiving trastuzamab

          -  Pregnancy or lactation

          -  Claustrophobia

          -  Inability to lie flat for 60-90 minutes

          -  Renal dysfunction with eGFR &lt;60 mL/min/1.73 m2

          -  Allergy to gadolinium containing contrast media

          -  Implanted devices, metallic hazards or other conditions presenting a contraindication
             to 3Tesla cardiac MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shruti Jolly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 14, 2017</study_first_submitted>
  <study_first_submitted_qc>April 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2017</study_first_posted>
  <last_update_submitted>August 21, 2019</last_update_submitted>
  <last_update_submitted_qc>August 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

